Pharma BD Deal Intelligence
Astellas CEO Hatanaka cited fidaxomicin's 'highly differentiated clinical profile' from US and EU studies as a basis for Japan launch confidence.
Optimer CEO Pedro Lichtinger said the partnership helps 'realize the potential of fidaxomicin to meet the serious unmet needs of CDI patients in Japan,' while…
8-K exhibit discloses the Astellas collaboration as expanding fidaxomicin's global reach into Japan, detailing upfront and milestone consideration up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Optimer-Astellas exclusive license to develop and commercialize fidaxomicin in Japan for CDI. $20M upfront, up to $70M regulatory/commercial milestones, plus double-digit royalty equivalent on Astellas Japan net sales.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. (this deal) | 2012 | $90M | 38 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2012 deals · Astellas Pharma Inc. deals · Infectious Disease deals